巨型综合体保护ER-alpha免受Fulvestrant在上皮卵巢癌中的降解
Sushil Kumar Jaiswal1, Kevin Fedkenheuer1, Ronak Khamar1
1Translational and Functional Genomics Branch, National Human Genome Research Institute, Bethesda, MD, 20892, USA.
Cancer letters
|July 24, 2024
概括
由于核雌激素受体α (ERα) 在蛋白质复合体内,卵巢癌细胞对Fulvestrant (ICI) 具有抗性. 将ICI与JQ1药物结合起来可以克服这种抗药性,提供一种新的治疗策略.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
背景情况:
- 卵巢癌对向雌激素受体α (ERα) 的激素治疗反应有限.
- 富尔韦斯坦 (ICI) 是治疗ERα阳性癌症的治疗药物,但耐药性机制尚未完全理解.
- 核ERα似乎比细胞质ERα对ICI降解的敏感性较小,这表明核局部化有助于抵抗.
研究的目的:
- 在卵巢癌中研究ERα对富尔韦斯坦抗性的机制.
- 为了确定参与ERα介导药物耐药性的蛋白质复合体.
- 评估ICI与超强增强抑制剂 (JQ1) 结合在克服抗性的有效性.
主要方法:
- 尺寸排除色谱 (SEC) 用于识别蛋白质复合体.
- 染色体免疫沉测序 (ChIP-seq) 用于绘制大复合体结合部位的地图.
- RNA测序 (RNA-seq) 和质谱学用于分析途径丰富和蛋白质降解.
- 细胞增殖和活力测试用于评估治疗疗效.
主要成果:
- 在卵巢癌细胞中发现了一种含有ERα,FOXA1和PITX1的1.3 MDa大复合体.
- 大复合体结合的ERα对ICI诱导的降解具有较强的抗性.
- 与ICI和JQ1的联合治疗显著增强了来自Megacomplex和其他细胞组件的ERα降解.
- 组合疗法有效抑制了卵巢癌细胞的增殖和活力.
结论:
- 含有ERα的Megacomplex在ERα驱动的染色质调节中发挥作用,并在卵巢癌中对Fulvestrant产生抗性.
- 将Fulvestrant (ICI) 与JQ1结合,代表了一种新的治疗策略,通过针对大复合体内的ERα来克服药物耐药性.
- 这种方法为治疗抗ERα的卵巢癌提供了新的脆弱性.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancer-Critical Genes II: Tumor Suppressor Genes
7.4K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.4K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancer Vaccines
348
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
348


